The Biologics Price Competition and Innovation Act (BPCIA) of 2009 aims to create a regulatory pathway for biosimilar products, which are highly similar to already approved biological products, to enter the market. This act seeks to balance the need for innovation in biologics with the desire to reduce healthcare costs by increasing competition through the introduction of biosimilars.